Are the MIA and MSKCC nomograms useful in selecting patients with melanoma for sentinel lymph node biopsy?

Sharif HoseinHarrison M DrebinNicholas R KurtanskyRoger Olofsson BaggeDaniel G CoitMadalyn G NeuwirthMichael A Marchetti

Published in: Journal of surgical oncology (2023)

Based on published data, use of the MIA or MSKCC nomograms as decision-making tools for SLNB at risk thresholds of 5%-10% does not clearly provide clinical benefit to patients.

Keyphrases

sentinel lymph node
end stage renal disease
decision making
newly diagnosed
ejection fraction
chronic kidney disease
early stage
lymph node
neoadjuvant chemotherapy
randomized controlled trial
ultrasound guided
big data
artificial intelligence